Stocks and Investing Stocks and Investing
Wed, April 2, 2014
Tue, April 1, 2014
Mon, March 31, 2014
Fri, March 28, 2014
Thu, March 27, 2014
Wed, March 26, 2014
Tue, March 25, 2014
Mon, March 24, 2014
Fri, March 21, 2014
Thu, March 20, 2014
Wed, March 19, 2014
Tue, March 18, 2014
Mon, March 17, 2014
Fri, March 14, 2014
Wed, March 12, 2014
Tue, March 11, 2014
Mon, March 10, 2014
Fri, March 7, 2014
Thu, March 6, 2014
Wed, March 5, 2014
Tue, March 4, 2014
Mon, March 3, 2014
Fri, February 28, 2014
Thu, February 27, 2014
Wed, February 26, 2014
Tue, February 25, 2014
Mon, February 24, 2014
Fri, February 21, 2014
Thu, February 20, 2014
Wed, February 19, 2014
Tue, February 18, 2014
Mon, February 17, 2014
Fri, February 14, 2014

Evan Seigerman Maintained (BIIB) at Buy with Increased Target to $400 on, Feb 14th, 2014


Published on 2024-10-25 04:18:28 - WOPRAI, Evan Seigerman
  Print publication without navigation


Evan Seigerman of Credit Suisse, Maintained "Biogen Inc." (BIIB) at Buy with Increased Target from $375 to $400 on, Feb 14th, 2014.

Evan has made no other calls on BIIB in the last 4 months.



There are 3 other peers that have a rating on BIIB. Out of the 3 peers that are also analyzing BIIB, 0 agree with Evan's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Evan


  • Andrew Peters of "Deutsche Bank" Maintained at Strong Buy with Increased Target to $415 on, Tuesday, January 28th, 2014
  • Christopher Marai of "Nomura" Initiated at Strong Buy and Held Target at $368 on, Wednesday, January 8th, 2014
  • Christopher Raymond of "Piper Sandler" Initiated at Buy on, Tuesday, November 26th, 2013